Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs Snowflake Inc (SNOW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs Snowflake Inc — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $105.11 (market cap $8.88B), while Snowflake Inc trades at $327.09 (market cap $118.22B). The key difference: Snowflake Inc is far larger — about 13.3× Kymera Therapeutics Inc. Common Stock's market cap, and Snowflake Inc is trading nearer its 52-week high, Kymera Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and Snowflake Inc for 53 Days on average.
| KYMR | SNOW | |
|---|---|---|
Market Cap | $8.88B | $118.22B |
Volume | 1,028,790 | 4,578,402 |
Sector | Health | Technology |
52-Week High | $127.31 | $368.89 |
52-Week Low | $55.80 | $121.11 |
Typical Hold Time | 0 Days | 53 Days |
Enterprise Value | $8.27B | $118.64B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Snowflake (SNOW) trades at $357.76, down 0.72% today, with strong technical momentum showing bullish moving averages and support at $355. The company demonstrates robust revenue growth, reaching $3.63 billion in 2025, though it remains unprofitable with a -20.07% net margin. Recent earnings have consistently beaten expectations, and analyst sentiment is overwhelmingly positive with 81% buy ratings and a $418.03 consensus target.
The outlook remains constructive given strong revenue growth and strategic partnerships, but investors face risks from continued losses, high valuation multiples (P/S 22.66), and potential dilution from the recent $3.75 billion convertible note offering. The stock offers growth exposure but requires tolerance for current profitability challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About Snowflake Inc
Founded in 2012, Snowflake is a data lake, warehousing, and sharing company that came public in 2020. To date, the company has over 3,000 customers including nearly 30% of the Fortune 500 as its customers. Snowflake's data lake stores unstructured and semistructured data that can then be used in analytics to create insights stored in its data warehouse. Snowflake's data sharing capability allows enterprises to easily buy and ingest data almost instantaneously compared with a traditionally months-long process. Overall, the company is known for the fact that all of its data solutions that can be hosted on various public clouds.
Read more on SNOW →
